Axiom Investors LLC DE Sells 8,419 Shares of United Therapeutics Corporation $UTHR

Key Points

• Axiom Investors LLC DE reduced its holdings in United Therapeutics Corporation by 83.9%, selling 8,419 shares, leaving them with 1,621 shares worth approximately $500,000.
• United Therapeutics experienced mixed analyst ratings: UBS raised their price target to $415 while Morgan Stanley and Bank of America lowered theirs to $328 and $315, respectively.
• Despite a missed earnings estimate with reported EPS of $6.41 against an expectation of $6.80, revenue increased by 11.7% year-over-year, totaling $798.60 million for the quarter.

Axiom Investors LLC DE reduced its position in shares of United Therapeutics Corporation (NASDAQ:UTHR - Free Report) by 83.9% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 1,621 shares of the biotechnology company's stock after selling 8,419 shares during the quarter. Axiom Investors LLC DE's holdings in United Therapeutics were worth $500,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in UTHR. SVB Wealth LLC bought a new stake in United Therapeutics during the 1st quarter worth about $32,000. Dunhill Financial LLC grew its position in shares of United Therapeutics by 100.0% during the 4th quarter. Dunhill Financial LLC now owns 100 shares of the biotechnology company's stock worth $35,000 after buying an additional 50 shares during the period. Sound Income Strategies LLC acquired a new position in shares of United Therapeutics during the 1st quarter worth about $49,000. Brooklyn Investment Group grew its position in shares of United Therapeutics by 103.2% during the 1st quarter. Brooklyn Investment Group now owns 193 shares of the biotechnology company's stock worth $59,000 after buying an additional 98 shares during the period. Finally, State of Wyoming acquired a new position in shares of United Therapeutics during the 4th quarter worth about $62,000. 94.08% of the stock is owned by institutional investors.

United Therapeutics Price Performance

NASDAQ:UTHR traded down $2.26 during trading hours on Friday, reaching $304.99. 253,418 shares of the stock were exchanged, compared to its average volume of 530,833. United Therapeutics Corporation has a twelve month low of $266.98 and a twelve month high of $417.82. The firm has a 50 day moving average of $298.38 and a 200 day moving average of $306.47. The stock has a market cap of $13.76 billion, a PE ratio of 11.90, a PEG ratio of 4.63 and a beta of 0.57.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last released its quarterly earnings results on Wednesday, July 30th. The biotechnology company reported $6.41 earnings per share for the quarter, missing analysts' consensus estimates of $6.80 by ($0.39). United Therapeutics had a return on equity of 18.73% and a net margin of 40.36%.The firm had revenue of $798.60 million for the quarter, compared to analyst estimates of $802.13 million. During the same period last year, the company earned $5.85 EPS. The company's revenue was up 11.7% compared to the same quarter last year. Equities research analysts anticipate that United Therapeutics Corporation will post 24.48 earnings per share for the current year.

Wall Street Analysts Forecast Growth

UTHR has been the subject of several analyst reports. Wells Fargo & Company decreased their target price on United Therapeutics from $314.00 to $295.00 and set an "equal weight" rating for the company in a research report on Thursday, July 31st. HC Wainwright set a $400.00 target price on United Therapeutics and gave the stock a "buy" rating in a research report on Thursday, July 31st. JPMorgan Chase & Co. decreased their target price on United Therapeutics from $350.00 to $330.00 and set an "overweight" rating for the company in a research report on Tuesday, July 8th. UBS Group boosted their price objective on United Therapeutics from $385.00 to $415.00 and gave the company a "buy" rating in a research report on Wednesday, August 13th. Finally, Morgan Stanley decreased their price objective on United Therapeutics from $348.00 to $328.00 and set an "equal weight" rating for the company in a research report on Thursday, July 10th. Nine analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company's stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $382.00.

Insider Buying and Selling

In related news, EVP Paul A. Mahon sold 11,000 shares of the stock in a transaction on Thursday, August 21st. The stock was sold at an average price of $308.75, for a total value of $3,396,250.00. Following the sale, the executive vice president owned 36,781 shares in the company, valued at approximately $11,356,133.75. This represents a 23.02% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Richard Giltner sold 3,036 shares of the stock in a transaction on Tuesday, June 24th. The shares were sold at an average price of $289.60, for a total value of $879,225.60. Following the completion of the sale, the director owned 19,384 shares in the company, valued at approximately $5,613,606.40. This trade represents a 13.54% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 81,681 shares of company stock worth $24,537,839. 10.30% of the stock is owned by corporate insiders.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.